Atara Biotherapeutics, Inc.

ATRASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1604464

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$8.6M	—	—	—	—
Research and Development Expense	$224.8M	$272.5M	$244.7M	$216.1M	$167.5M
Operating Expenses	—	—	$309.1M	$295.7M	$237.1M
Operating Income (Loss)	-$276.0M	-$280.5M	-$309.1M	-$295.7M	-$237.1M
Interest Expense	$5.3M	$373.0K	—	—	—
Other Nonoperating Income (Expense)	-$246.0K	-$700.0K	$2.4M	$4.7M	$6.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$276.1M	-$228.3M	-$306.6M	-$291.0M	-$230.7M
Income Tax Expense (Benefit)	$15.0K	$12.0K	$15.0K	$12.0K	-$44.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$165.5M	$376.4M	$468.1M	$588.1M	$342.9M
Assets, Current	$101.9M	$295.1M	$384.6M	$523.3M	$273.0M
Cash and Cash Equivalents, at Carrying Value	$25.8M	$92.9M	$106.1M	$200.4M	$74.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$34.1M	$40.2M	$986.0K	$1.3M	$0.00
Inventory, Net	$9.7M	$1.6M	$0.00	—	—
Liabilities	$264.7M	$249.8M	$188.5M	$125.8M	$52.2M
Liabilities, Current	$142.2M	$78.9M	$105.8M	$82.9M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$193.0M	-$270.4M	-$180.8M	-$235.6M	-$179.8M
Net Cash Provided by (Used in) Investing Activities	$123.9M	$203.0M	-$120.7M	$60.5M	-$196.3M
Net Cash Provided by (Used in) Financing Activities	$2.0M	$53.1M	$427.6M	$188.8M	$357.5M
Payments to Acquire Property, Plant, and Equipment	$1.2M	$4.2M	$4.5M	$5.7M	$35.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)